Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Moderate Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) has been given a consensus recommendation of “Moderate Buy” by the eight brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $173.88.

Several brokerages have recently weighed in on ASND. Citigroup upped their target price on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Wells Fargo & Company lifted their price objective on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Cantor Fitzgerald restated an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a research note on Friday, May 3rd. Finally, Wedbush lifted their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th.

Ascendis Pharma A/S Stock Down 1.5 %

Ascendis Pharma A/S stock opened at $133.93 on Friday. The firm has a fifty day moving average of $145.55 and a 200-day moving average of $128.74. Ascendis Pharma A/S has a 52-week low of $83.75 and a 52-week high of $161.00. The firm has a market capitalization of $7.80 billion, a P/E ratio of -13.94 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The firm had revenue of $148.62 million during the quarter, compared to the consensus estimate of $97.02 million. On average, research analysts expect that Ascendis Pharma A/S will post -4.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

Institutional investors have recently modified their holdings of the stock. Certuity LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter worth about $270,000. Invesco Ltd. raised its position in shares of Ascendis Pharma A/S by 9.3% during the 3rd quarter. Invesco Ltd. now owns 672,126 shares of the biotechnology company’s stock valued at $62,938,000 after acquiring an additional 57,413 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in Ascendis Pharma A/S during the third quarter worth $1,810,000. Schonfeld Strategic Advisors LLC boosted its holdings in Ascendis Pharma A/S by 24.7% in the third quarter. Schonfeld Strategic Advisors LLC now owns 38,900 shares of the biotechnology company’s stock worth $3,643,000 after purchasing an additional 7,700 shares during the period. Finally, Sequoia Financial Advisors LLC bought a new stake in Ascendis Pharma A/S during the fourth quarter valued at $732,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.